Concepedia
Statistics
Publications
12
Citations
929
H-Index
Active since
2001
Affiliations
Cancer Research UK(Current)
The Francis Crick Institute
AstraZeneca (United Kingdom)
Cancer Research UK Scotland Institute
University College London
Mark Charles is an author at Cancer Research UK specializing in medicine, natural sciences, and pharmacology.
Top concepts
MedicinePharmacologyNatural SciencesDrug DiscoveryPharmacotherapyDrug DevelopmentMedicinal ChemistryBiochemistryCell BiologyTumor Biology
Publications per year
2001–2022
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Diana Zatreanu, Helen M.R. Robinson, Omar Alkhatib et al. · Nature Communications · 2021 · 336 citations · Full text
A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth <i>In vitro</i> and <i>In vivo</i>
Kuzhuvelil B. Harikumar, Ajaikumar B. Kunnumakkara, Nobuo Ochi et al. · Molecular Cancer Therapeutics · 2010 · 170 citations · Full text
Identifying strategies to target the metabolic flexibility of tumours
Andrés Méndez‐Lucas, Wei Lin, Paul C. Driscoll et al. · Nature Metabolism · 2020 · 140 citations · Full text
Metabolic Remodeling, Metabolic Pathway Analysis, Metabolic Flexibility +5
LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation
Katerina Mardilovich, Mark Baugh, Diane Crighton et al. · Oncotarget · 2015 · 48 citations · Full text
Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cells
Ian Evans, Azadeh Bagherzadeh, Mark Charles et al. · Biochemical Journal · 2010 · 44 citations · Full text
Endothelial Cells, Cellular Physiology, Molecular Pharmacology +17
1–5 of 12